A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

Recruiting now · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

Key facts

Study ID

NCT07524348

Run by

Samsung Bioepis Co., Ltd.

People needed

149

Starts

2026-03-23

Expected to finish

2030-07-01

Last updated by the study team

2026-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically-confirmed, locally advanced (unresectable) or metastatic solid tumors with recurrence or progression during or after standard therapy, intolerance to standard therapy, refused to receive standard therapy, or for whom no standard therapy is available.

You may not qualify if…

• Have spinal cord compression or clinically active central nervous system metastases
• Have leptomeningeal disease
• Have thromboembolic or clinically significant bleeding events
• Have significant cardiovascular disease
• Have an active autoimmune disease

Where it is running

• Research Site — Scottsdale, Arizona, United States (enrolling)
• Research Site — Fairfax, Virginia, United States (enrolling)
• Research Site — Adelaide, Australia (enrolling)
• Research Site — Melbourne, Australia (enrolling)
• Research Site — Barcelona, Spain (enrolling)
• Research Site — Madrid, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.